Abbott is investigating a cyber incident involving unauthorized access to a limited number of internal systems in its cancer diagnostics business.
The incident does not affect business operations, product availability, manufacturing, lab operations or the company’s ability to serve patients, according to Abbott’s July 16 statement. No other Abbott businesses, sites or systems were affected, and the legacy Exact Sciences systems are separate from Abbott’s own.
Abbott said it engaged third-party cybersecurity experts and law enforcement upon learning of the incident and is continuing to investigate what information was accessed. The company does not expect any material impact on its business or financial results at this time.
